FMFS was tested on two Alzheimer’s Disease Neuroimaging Initiative (ADNI) cohorts to understand hippocampal alterations that relate to Aβ/tau depositions. The gene discussed is MAPT; the disease is early-onset autosomal dominant Alzheimer disease.